Skip to main content

Table 5 Univariate prognostic factor analysis

From: The role of radiotherapy in the management of POEMS syndrome

Factor No. of case 3-year PFS (%) p value * 3-year OS (%) p value *
Age >50 years (vs. ≤50 years) 13/20 53.3/62.4 0.931 56.4/66.0 0.259
Radiotherapy (Y/N) 13/20 64.8/56.7 0.310 66.6/59.4 0.782
Chemotherapy (Y/N) 25/8 71.5/17.5 0.007 74.1/18.2 0.020
HD Chemotherapy with ABSCT (vs. SD chemotherapy) 15/10 80.8/58.3 0.291 78.8/66.7 0.253
IgG M-protein subtype (vs. other subtypes) 17/16 54.4/65.6 0.719 61.1/65.8 0.775
VEGF elevation without gross lesion (vs. other subtypes) 6/27 25.0/66.0 0.035 16.7/74.1 0.008
BM plasma cells more than 5% (vs. ≤5%) 13/20 61.4/59.5 0.771 60.6/62.5 0.821
The presence of abnormal clonal plasma cells in BM (Y/N) 5/28 60.0/60.8 0.249 80.0/60.4 0.552
Extravascular volume overload except peripheral edema (Y/N) 16/17 49.2/70.0 0.155 53.5/71.1 0.212
Number of POEMS features >7 (vs. ≤7) 14/19 46.4/67.7 0.220 45.9/74.2 0.127
Multiple bone lesions (vs. single bone lesion) 12/11 62.3/66.3 0.742 77.9/70.7 0.906
  1. PFS, progression free survival; OS, overall survival; ABSCT, autologous peripheral blood stem cell transplantation; SD, standard dose; Ig, immunoglobulin; VEGF, vascular endothelial growth factor; BM, bone marrow.
  2. *Log-rank test.